Biodexa Pharmaceuticals Plc (BDRX)

Market Cap	191.13K
Revenue (ttm)	482,278
Net Income (ttm)	-8.96M
Shares Out	236.51K
EPS (ttm)	-9.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,418
Open	0.765
Previous Close	0.780
Day's Range	0.765 - 0.831
52-Week Range	0.719 - 21.440
Beta	1.57
Analysts	Strong Buy
Price Target	8.00 (+925.64%)
Earnings Date	May 7, 2024

About BDRX

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solub...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 27
• Stock Exchange: NASDAQ
• Ticker Symbol: BDRX

Financial Performance

In 2023, BDRX's revenue was 381,000, a decrease of -45.49% compared to the previous year's 699,000. Losses were -7.08 million, -7.54% less than in 2022.

Financial numbers in GBP

Analyst Forecast

According to one analyst, the rating for BDRX stock is "Strong Buy" and the 12-month stock price forecast is $8.0.

Price Target

$8.0

(925.64% upside)

Analyst Consensus: Strong Buy